GT160-246, a high-molecular-weight soluble anionic polymer, was tested in v
itro and in vivo for neutralization of Clostridium difficile toxin A and B
activities. Five milligrams of GT160-246 per mi neutralized toxin-mediated
inhibition of protein synthesis in Vero cells induced by 5 mug of toxin A p
er mi or 1.25 ng of toxin B per mi. Tn ligated rat ileal loops, 1 mg of GT1
60-246 neutralized fluid accumulation caused by 5 mug of toxin A. At doses
as high as 80 mg/loop, cholestyramine provided incomplete neutralization of
fluid accumulation caused by 5 mug of toxin A. GT160-246 protected 80% of
the hamsters from mortality caused by infection with C. difficile, whereas
cholestyramine protected only 10% of animals. Treatment of C. difficile-inf
ected hamsters with metronidazole initially protected 100% of the hamsters
from mortality, but upon removal of treatment, 80% of the hamsters had rela
pses and died. In contrast, removal of GT160-246 treatment did not result i
n disease relapse in the hamsters. GT160-246 showed no antimicrobial activi
ty in tests with a panel of 16 aerobic bacteria and yeast and 22 anaerobic
bacteria and did not interfere with the in vitro activities of most antibio
tics. GT160-246 offers a novel, nonantimicrobial treatment of C. difficile
disease in humans.